2 terminated. 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Terminated 2 |
Follow SEL: new trials by email Literature Review of SEL trials Research Report on SEL
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety and Efficacy of Selonsertib in Adults With Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) Fibrosis SEL, Placebo to match SEL 6 mg, Placebo to match SEL 18 mg - Nonalcoholic Steatohepatitis | Phase 3 | Terminated | Gilead Sciences | 808 | 2017-02-13 | 2020-06-29 |
| Safety and Efficacy of Selonsertib in Adults With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) SEL, Placebo to match SEL 6 mg, Placebo to match SEL 18 mg - Nonalcoholic Steatohepatitis | Phase 3 | Terminated | Gilead Sciences | 883 | 2017-01-30 | 2020-05-07 |
Non-alcoholic Fatty Liver Disease (2)
Gilead Sciences (2)
Australia (2) · Austria (2) · Belgium (2) · Canada (2) · France (2) · Germany (2) · Hong Kong (2) · India (2) · Israel (2) · Italy (2) · Japan (2) · Mexico (2) · New Zealand (2) · Poland (2) · Puerto Rico (2)
PMID 30639779, PMID 30779990, PMID 31271665, PMID 32147362, PMID 33307033, PMID 36750244
2016 (2)